Peter the Bridge, Saint Petersburg, Russia

News from NEOMED

ARTELO BIOSCIENCES AND THE NEOMED INSTITUTE ENTER INTO AN EXCLUSIVE GLOBAL OPTION AND LICENSE AGREEMENT

January 30th, 2018 |Announcement| No Comments

Artelo to advance NEOMED's NEO1940 novel, peripherally restricted, CB1/CB2 agonist, clinic-ready drug candidate for the treatment of patients suffering from cancer and anorexia/weight loss associated with cancer

La Jolla, CA, USA / Montreal, QC, Canada - January 30, 2018

Read complete news

NEO6860 Phase II Data to be Presented at the American College of Rheumatology’s Annual Meeting

November 22nd, 2017 | No Comments
- An analgesic effect demonstrated - - No increase in body temperature nor change in heat pain perception - Montreal, October 30, 2017 - The NEOMED Institute announced today that it will present a poster on the Phase II data for its lead program NEO6860 during the American College of Rheumatology’s A

Read complete news

The NEOMED Institute is Attending the 23rd Annual BioEurope Partnering Conference

|Announcement| No Comments
NEOMED’s 3 key partnering objectives: • Identify licensing partners/financial partners for NEOMED’s therapeutic pipeline • Identify promising in-licensing opportunities • Showcase NEOMED Innovation Center’s expansion project Montreal, October 25th, 2017 - The NEOMED Institute announced today

Read complete news

NEO6860 Clinical Results to be Presented at the Pain & Migraine Therapeutics Summit

February 27th, 2018 |Announcement| No Comments
- NEO6860 is a modality selective TRPV1 antagonist explored for the treatment of OA pain - - A phase II PoC Study is now completed - - NEO6860 is safe and exhibits an analgesic effect - Montreal, September 20, 2017 - The NEOMED Institute announced today that it will present two posters on the clini

Read complete news

© 2018 NEOMED Institute. All Rights Reserved. // Solutions Web Globalia